ADC Therapeutics (ADCT) Gains from Investment Securities: 2021-2023
Historic Gains from Investment Securities for ADC Therapeutics (ADCT) over the last 2 years, with Dec 2023 value amounting to $279,000.
- ADC Therapeutics' Gains from Investment Securities rose 102.43% to $279,000 in Q4 2023 from the same period last year, while for Dec 2023 it was -$497,000, marking a year-over-year increase of 95.68%. This contributed to the annual value of $1.2 million for FY2024, which is 334.00% up from last year.
- Latest data reveals that ADC Therapeutics reported Gains from Investment Securities of $279,000 as of Q4 2023, which was up 299.29% from -$140,000 recorded in Q3 2023.
- ADC Therapeutics' Gains from Investment Securities' 5-year high stood at $279,000 during Q4 2023, with a 5-year trough of -$11.5 million in Q4 2022.
- Over the past 3 years, ADC Therapeutics' median Gains from Investment Securities value was -$14,406 (recorded in 2022), while the average stood at -$1.5 million.
- Per our database at Business Quant, ADC Therapeutics' Gains from Investment Securities slumped by 21,684,086.79% in 2022 and then surged by 102.43% in 2023.
- ADC Therapeutics' Gains from Investment Securities (Quarterly) stood at -$53 in 2021, then crashed by 21,684,086.79% to -$11.5 million in 2022, then soared by 102.43% to $279,000 in 2023.
- Its Gains from Investment Securities stands at $279,000 for Q4 2023, versus -$140,000 for Q3 2023 and -$20,000 for Q2 2023.